Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.

Tel-Aviv Sourasky Medical Center20 enrolled

Overview

The investigators will compare the common treatment for cutaneous leishmaniasis with intra-lesional Pentostam to fractional CO2 laser with topical application of Pentostam. Outcome will be final scar appearance assesd by two dermatologist and pain measurement by VAS.

20 healthy patients diagnosed will cutaneous leishmaniasis with more than one lesion will be recruited. Half of the lesions will be treated with intra-lesional injections of Pentostam, and the other half by CO2 laser with topical application of Pentostam. Each lesion will recieve 3 treatments, one month apart between treatments. The patients will scale pain level of each treatment. Final scar appearance will be assessed by two dermatologists, without knowing what treatment was applied to each lesion.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Leishmaniasis

Interventions

Local application pentostamDRUG

intra-lisional pentostamDRUG

fractional CO2 laserDEVICE

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Objective cutaneous leishmaniasis diagnosis. * More than one Lesion Exclusion Criteria: * Previous treatment * Abnormal scarring

Outcomes

Primary Outcomes

scar appearance

Each lesion will be photographed prior to treatment and at 6th month (Three months after last (3rd) treatment).Two dermatologist will asses each lesion outcome

Time frame: At sixth month

Secondary Outcomes

Pain assessed by VAS

Time frame: at one month, two months, and three months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.